Navigation überspringen
Universitätsbibliothek Heidelberg
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Erdmann, Stella [VerfasserIn]   i
 Kirchner, Marietta [VerfasserIn]   i
 Götte, Heiko [VerfasserIn]   i
 Kieser, Meinhard [VerfasserIn]   i
Titel:Optimal designs for phase II/III drug development programs including methods for discounting of phase II results
Verf.angabe:Stella Erdmann, Marietta Kirchner, Heiko Götte, Meinhard Kieser
E-Jahr:2020
Jahr:09 October 2020
Fussnoten:Gesehen am 04.11.2020
Titel Quelle:Enthalten in: BMC medical research methodology
Ort Quelle:London : BioMed Central, 2001
Jahr Quelle:2020
Band/Heft Quelle:20(2020) Artikel-Nummer 253, 14 Seiten
ISSN Quelle:1471-2288
Abstract:Go/no-go decisions after phase II and sample size chosen for phase III are usually based on phase II results (e.g., the treatment effect estimate of phase II). Due to the decision rule (only promising phase II results lead to phase III), treatment effect estimates from phase II that initiate a phase III trial commonly overestimate the true treatment effect. Underpowered phase III trials are the consequence. Optimistic findings may then not be reproduced, leading to the failure of potentially expensive drug development programs. For some disease areas these failure rates are described to be quite high: 62.5%.
DOI:doi:10.1186/s12874-020-01093-w
URL:kostenfrei: Volltext: https://doi.org/10.1186/s12874-020-01093-w
 DOI: https://doi.org/10.1186/s12874-020-01093-w
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1737749599
Verknüpfungen:→ Zeitschrift
 
 
Lokale URL UB: Zum Volltext

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68657338   QR-Code
zum Seitenanfang